HK1254338A1 - 儲存穩定的組合物及治療眼睛屈光不正的方法 - Google Patents

儲存穩定的組合物及治療眼睛屈光不正的方法

Info

Publication number
HK1254338A1
HK1254338A1 HK18113414.1A HK18113414A HK1254338A1 HK 1254338 A1 HK1254338 A1 HK 1254338A1 HK 18113414 A HK18113414 A HK 18113414A HK 1254338 A1 HK1254338 A1 HK 1254338A1
Authority
HK
Hong Kong
Prior art keywords
eye
treatment
methods
storage stable
refractive errors
Prior art date
Application number
HK18113414.1A
Other languages
English (en)
Inventor
Gerald Horn
Lee Nordan
Original Assignee
Presbyopia Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/742,903 external-priority patent/US9320709B2/en
Priority claimed from US14/742,921 external-priority patent/US9314427B2/en
Application filed by Presbyopia Therapies Llc filed Critical Presbyopia Therapies Llc
Publication of HK1254338A1 publication Critical patent/HK1254338A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18113414.1A 2015-06-18 2018-10-18 儲存穩定的組合物及治療眼睛屈光不正的方法 HK1254338A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/742,903 US9320709B2 (en) 2013-08-28 2015-06-18 Storage stable compositions and methods for the treatment of refractive errors of the eye
US14/742,921 US9314427B2 (en) 2013-08-28 2015-06-18 Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
PCT/US2016/036687 WO2016205068A1 (en) 2015-06-18 2016-06-09 Storage stable compositions and methods for the treatment of refractive errors of the eye

Publications (1)

Publication Number Publication Date
HK1254338A1 true HK1254338A1 (zh) 2019-07-19

Family

ID=57545598

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113414.1A HK1254338A1 (zh) 2015-06-18 2018-10-18 儲存穩定的組合物及治療眼睛屈光不正的方法

Country Status (9)

Country Link
EP (3) EP3310356A4 (zh)
JP (3) JP6838712B2 (zh)
KR (4) KR102667598B1 (zh)
CN (3) CN107847492B (zh)
AU (2) AU2016280616B2 (zh)
CA (2) CA2987787C (zh)
HK (1) HK1254338A1 (zh)
MX (2) MX2017016518A (zh)
WO (2) WO2016205069A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987787C (en) * 2015-06-18 2023-06-27 Presbyopia Therapies, LLC Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
CN110505876A (zh) * 2017-03-23 2019-11-26 新加坡保健服务集团 包含噻托铵作为活性成分的用于预防近视、治疗近视、及/或预防近视进展的药剂
CN110621298B (zh) 2017-05-11 2022-12-20 维卢玛有限公司 阿托品药物组合物
AU2019357979A1 (en) * 2018-10-10 2021-04-29 Lenz Therapeutics Operations, Inc. Compositions and methods for the treatment of presbyopia
JP2022511051A (ja) * 2018-12-05 2022-01-28 レンズ・セラピューティクス・インコーポレイテッド キヌクリジン環含有ムスカリン性アゴニストのプロドラッグ及びその組成物ならびに方法
EP4228636A1 (en) * 2020-10-13 2023-08-23 Lenz Therapeutics, Inc. Compositions and methods for storage stable ophthalmic drugs
CR20230190A (es) * 2020-11-02 2023-09-06 Visus Therapeutics Inc Compuesto degradante en un medicamento
CN117157056A (zh) * 2021-03-16 2023-12-01 维卢玛有限公司 用于眼用组合物的多剂量容器
KR20220154509A (ko) 2021-05-13 2022-11-22 전연우 복용 시간을 알려주고 편하게 약을 꺼낼 수 있는 약통
TW202333700A (zh) * 2021-12-16 2023-09-01 美商倫茨治療公司 用於治療眼病之組成物及方法
KR20230126522A (ko) * 2022-02-23 2023-08-30 주식회사 스카이테라퓨틱스 고분자 히알루론산의 구조체, 이의 제조방법 및 이를 포함하는 점안 조성물
KR20230126461A (ko) * 2022-02-23 2023-08-30 주식회사 스카이테라퓨틱스 고분자 히알루론산의 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
KR20020050239A (ko) * 1999-11-09 2002-06-26 구이도 콜러, 스테판 바슬러 하이드록시에이코사테트라엔산 유도체를 함유하는 조성물및 안구 건조증 치료에서의 사용 방법
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
WO2004058289A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US7830573B2 (en) 2005-11-03 2010-11-09 Stamper Technologies, Inc. Method and system for producing multiple images in a single image plane using diffraction
DK1938839T3 (da) 2006-12-18 2009-11-30 Jorge Luis Benozzi Oftalmiske sammensætninger af parasympatiske stimulanter og anti-inflammatoriske midler til anvendelse i behandlingen af presbyopi
WO2009072007A2 (en) * 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2758047B1 (en) 2011-09-20 2018-12-19 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
JP2014528465A (ja) * 2011-10-12 2014-10-27 アセンディス ファーマ オフサルモロジー ディヴィジョン エー／エス 眼の状態の予防及び治療
DE102011121770A1 (de) 2011-12-21 2013-06-27 Oerlikon Trading Ag, Trübbach Homogenes HIPIMS-Beschichtungsverfahren
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US9573840B2 (en) * 2013-08-27 2017-02-21 Corning Incorporated Antimony-free glass, antimony-free frit and a glass package that is hermetically sealed with the frit
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CA2987787C (en) * 2015-06-18 2023-06-27 Presbyopia Therapies, LLC Compositions for the improvement of distance vision and the treatment of refractive errors of the eye

Also Published As

Publication number Publication date
AU2016280615B2 (en) 2020-10-01
EP3310356A1 (en) 2018-04-25
KR20180014825A (ko) 2018-02-09
KR20230156161A (ko) 2023-11-13
CA2987783A1 (en) 2016-12-22
AU2016280615A1 (en) 2017-12-14
JP6835747B2 (ja) 2021-02-24
MX2017016517A (es) 2018-05-28
EP4385521A2 (en) 2024-06-19
WO2016205068A1 (en) 2016-12-22
KR102667598B1 (ko) 2024-05-20
CN107847492B (zh) 2021-05-25
WO2016205069A1 (en) 2016-12-22
AU2016280616A1 (en) 2017-12-14
CN116808032A (zh) 2023-09-29
CA2987787A1 (en) 2016-12-22
EP3310356A4 (en) 2018-12-05
JP7026189B2 (ja) 2022-02-25
AU2016280616B2 (en) 2020-10-22
KR102598047B1 (ko) 2023-11-06
EP3310336A1 (en) 2018-04-25
JP2021035954A (ja) 2021-03-04
CN107847492A (zh) 2018-03-27
MX2017016518A (es) 2018-05-28
KR20180014824A (ko) 2018-02-09
JP2018517738A (ja) 2018-07-05
EP3310336A4 (en) 2018-12-05
BR112017025722A2 (pt) 2018-08-07
KR20230085217A (ko) 2023-06-13
JP6838712B2 (ja) 2021-03-03
CN107920984A (zh) 2018-04-17
CA2987787C (en) 2023-06-27
BR112017025726A2 (pt) 2018-08-14
JP2018517740A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
HK1254338A1 (zh) 儲存穩定的組合物及治療眼睛屈光不正的方法
HK1258205A1 (zh) 用於治療血紅蛋白病的組合物和方法
HK1252512A1 (zh) 向眼部遞送藥劑的方法
IL289099A (en) Methods for storage of whole blood, and corresponding preparations
IL252159B (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
HK1225654A1 (zh) 用於治療老花眼的組合物及方法
IL247931A0 (en) Stable compositions of unattached iodine and methods of use
IL246791A0 (en) Compositions and methods for treating eye diseases
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
SG11201708114SA (en) Ophthalmic compositions and methods of use therefor
SG11201609254YA (en) Therapeutic placental compositions, methods of making and methods of use
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
HK1258073A1 (zh) 治療細胞質糖原貯積失調的方法和組合物
IL248210A0 (en) Methods and preparations for the treatment of blood vessel malformations
IL246855A0 (en) Materials for use in the treatment of retinitis
EP3096742C0 (en) COMPOSITIONS AND METHODS FOR MODIFYING THE SURFACE OF CELLS, AND METHODS OF USE
HK1225994A1 (zh) 用於治療過敏性病症的組合物
IL248494A0 (en) Methods and compositions for the treatment of fat storage diseases
PT3229780T (pt) Composições oftálmicas para utilização no tratamento da síndrome de olhos secos
PL3297626T3 (pl) Kompozycja oftalmiczna zawierająca kwas liponowy i kwas hialuronowy
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201506967D0 (en) Treatment of optical aberration
GB201406623D0 (en) Treatment of optical aberration/s
GB201413538D0 (en) Ophthalmic compositions and uses thereof